Wilson disease affects thousands globally, yet up to 20% of patients remain undiagnosed despite carrying the genetic mutations responsible for this potentially fatal copper accumulation disorder. The diagnostic gap stems from variants that appear harmless in standard genetic tests but actually disrupt normal gene function through subtle splicing errors—changes invisible to conventional DNA sequencing. Researchers demonstrated that nasopharyngeal swabs—simple nasal samples—contain sufficient ATP7B gene transcripts to detect these hidden splicing defects using long-read nanopore sequencing technology. The team successfully identified mRNA splicing abnormalities in four Wilson disease patients whose genetic diagnosis had remained inconclusive through standard methods. Three seemingly harmless synonymous variants and one nonsense mutation all produced detectable splicing changes when analyzed from nasal swab RNA rather than genomic DNA alone. This breakthrough addresses a critical limitation in Wilson disease diagnosis. Previously, detecting splicing abnormalities required invasive liver biopsies since the ATP7B gene expresses predominantly in liver tissue. The discovery that nasopharyngeal tissue contains comparable transcript profiles transforms diagnostic accessibility while maintaining analytical precision. For Wilson disease patients, early accurate diagnosis enables prompt copper chelation therapy that prevents irreversible liver damage, neurological deterioration, and psychiatric manifestations. This RNA-based approach represents a paradigm shift from DNA-centric genetic testing toward functional transcript analysis. The methodology could extend beyond Wilson disease to other disorders where splicing variants contribute to diagnostic uncertainty, particularly conditions affecting tissues difficult to access safely.